Tyrosine Kinase Inhibitors and Vascular Toxicity: Impetus for a Classification System?

Research output: Contribution to journalReview articlepeer-review

25 Scopus citations


The introduction of molecularly targeted therapies with tyrosine kinase inhibitors has revolutionized cancer therapy and has contributed to a steady decline in cancer-related mortality since the late 1990s. However, not only cardiac but also vascular toxicity has been reported for these agents, some as expected on-target effects (e.g., VEGF receptor inhibitors) and others as unanticipated events (e.g., BCR-Abl inhibitors). A sound understanding of these cardiovascular toxic effects is critical to advance mechanistic insight into vascular disease and clinical care. From a conceptual standpoint, there might be value in defining type I (permanent) and type II (transient) vascular toxicity. This review will focus on the tyrosine kinase inhibitors in current clinical use and their associated vascular side effects.

Original languageEnglish (US)
Article number33
JournalCurrent oncology reports
Issue number6
StatePublished - Jun 1 2016


  • Angina
  • Cancer
  • Cardiomyopathy
  • Chemotherapy
  • Endothelial dysfunction
  • Myocardial infarction
  • Stroke
  • Thrombosis
  • Vasospasm

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Tyrosine Kinase Inhibitors and Vascular Toxicity: Impetus for a Classification System?'. Together they form a unique fingerprint.

Cite this